Aberdeen Group plc Has $215.76 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Key Points

• Aberdeen Group plc significantly reduced its holdings in Gilead Sciences by 48.7%, selling nearly 1.8 million shares during the first quarter.
• CEO Daniel O'Day recently sold 10,000 shares of Gilead stock for approximately $1.14 million, resulting in a 1.62% decrease in his ownership.
• Analysts have mixed ratings on Gilead, with a consensus of "Moderate Buy" and a price target of $114.82, following upgrades from firms like Needham and RBC.

Aberdeen Group plc trimmed its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 48.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,933,997 shares of the biopharmaceutical company's stock after selling 1,833,958 shares during the quarter. Aberdeen Group plc owned 0.16% of Gilead Sciences worth $215,757,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Vanguard Group Inc. raised its stake in shares of Gilead Sciences by 1.7% during the first quarter. Vanguard Group Inc. now owns 117,470,825 shares of the biopharmaceutical company's stock worth $13,162,606,000 after purchasing an additional 1,942,433 shares during the last quarter. Northern Trust Corp lifted its position in Gilead Sciences by 19.7% during the fourth quarter. Northern Trust Corp now owns 14,915,095 shares of the biopharmaceutical company's stock worth $1,377,707,000 after buying an additional 2,458,954 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Gilead Sciences by 15.1% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 12,234,672 shares of the biopharmaceutical company's stock worth $1,130,117,000 after buying an additional 1,605,730 shares during the period. Royal Bank of Canada raised its holdings in shares of Gilead Sciences by 30.1% in the 4th quarter. Royal Bank of Canada now owns 8,678,751 shares of the biopharmaceutical company's stock worth $801,655,000 after purchasing an additional 2,005,863 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Gilead Sciences in the first quarter valued at about $620,415,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on GILD shares. Royal Bank Of Canada lifted their target price on Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Morgan Stanley lifted their target price on Gilead Sciences from $130.00 to $135.00 and gave the stock an "overweight" rating in a report on Friday, April 25th. Daiwa Capital Markets upgraded Gilead Sciences from a "neutral" rating to an "outperform" rating and set a $128.00 price target on the stock in a report on Tuesday. UBS Group boosted their price target on Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a research report on Friday, August 8th. Finally, Oppenheimer cut their price objective on Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating for the company in a research report on Friday, April 25th. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and seven have given a Hold rating to the company. Based on data from MarketBeat, Gilead Sciences currently has a consensus rating of "Moderate Buy" and a consensus price target of $115.39.

Gilead Sciences Stock Down 0.0%

Shares of GILD traded down $0.01 during midday trading on Tuesday, hitting $117.98. The stock had a trading volume of 6,114,576 shares, compared to its average volume of 8,319,784. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15. The company has a 50 day simple moving average of $111.98 and a two-hundred day simple moving average of $108.64. The firm has a market cap of $146.39 billion, a price-to-earnings ratio of 23.50, a price-to-earnings-growth ratio of 0.73 and a beta of 0.33. Gilead Sciences, Inc. has a twelve month low of $74.34 and a twelve month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to the consensus estimate of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.Gilead Sciences's quarterly revenue was up 1.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.01 earnings per share. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, September 29th. Stockholders of record on Monday, September 15th will be given a $0.79 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences's dividend payout ratio is presently 62.95%.

Insider Transactions at Gilead Sciences

In other Gilead Sciences news, Director Jeffrey Bluestone sold 5,000 shares of the firm's stock in a transaction on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the sale, the director owned 8,920 shares of the company's stock, valued at approximately $978,880.80. This trade represents a 35.92% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Johanna Mercier sold 28,000 shares of the business's stock in a transaction dated Thursday, May 22nd. The stock was sold at an average price of $107.52, for a total value of $3,010,560.00. Following the transaction, the insider directly owned 121,152 shares of the company's stock, valued at approximately $13,026,263.04. The trade was a 18.77% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 110,000 shares of company stock worth $12,349,790 over the last three months. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.